ZZ06 / Changchun Intellicrown Pharma - LARVOL DELTA

ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Changchun Intellicrown Pharmaceutical Co. LTD | Trial completion date: Apr 2024 ➔ Jul 2026 | Trial primary completion date: Dec 2023 ➔ Dec 2025

Trial completion date • Trial primary completion date • Oncology • Solid Tumor

ZZ06 in Adult Patients With Advanced EGFR Positive Solid Tumor Malignancies (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Changchun Intellicrown Pharmaceutical Co. LTD | Trial completion date: Oct 2022 ➔ Apr 2024 | Trial primary completion date: Jun 2022 ➔ Dec 2023

Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

ZZ06 in Adult Patients With Advanced EGFR Positive Solid Tumor Malignancies (clinicaltrials.gov) - P1; N=60; Recruiting; Sponsor: Changchun Intellicrown Pharmaceutical Co. LTD; Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

ZZ06 in Adult Patients With Advanced EGFR Positive Solid Tumor Malignancies (clinicaltrials.gov) - P1; N=60; Not yet recruiting; Sponsor: Changchun Intellicrown Pharmaceutical Co. LTD; Initiation date: Nov 2020 ➔ Mar 2021

Clinical • Trial initiation date • Oncology • Solid Tumor

ZZ06 in Adult Patients With Advanced EGFR Positive Solid Tumor Malignancies (clinicaltrials.gov) - P1; N=60; Not yet recruiting; Sponsor: Changchun Intellicrown Pharmaceutical Co. LTD; Initiation date: Aug 2020 ➔ Nov 2020

Clinical • Trial initiation date • Oncology • Solid Tumor

ZZ06 in Adult Patients With Advanced EGFR Positive Solid Tumor Malignancies (clinicaltrials.gov) - P1; N=60; Not yet recruiting; Sponsor: Changchun Intellicrown Pharmaceutical Co. LTD

Clinical • New P1 trial • Oncology • Solid Tumor